| Faculty | Relationship Identified With: |
| Dr. Vijaya Raj Bhatt | Safety Monitoring Committee: Protagonist; Consultant: Imugene, Incyte, Abbvie, Genentech, Servier Pharmaceuticals; Institutional research support: Abbvie, Pfizer, Incyte, Jazz, and National Marrow Donor Program; Drug support (institutional) for a trial: Chimerix |
| Hossein Borghaei, DO, MS | Consultant/Advisor: Amgen; AstraZeneca; Axiom; Beigene; BioNTech; BMS; Boehringer Ingelheim; Daiichi; Da Volterra; EMD-Serono; Genentech; Genmab; Guardant; iTEO; Janssen; Jazz; Kriya; Lilly; Merck; Mirati; Natera; Novartis; Oncocyte; Pfizer; PharmaMar; Regeneron; Takeda: Grant/Research Support: BMS/Lilly; Merck/Celgene; Millennium; Stock Options: Nucleai; Sonnetbio; Rgenix |
| Alan Bryce, MD | Consultant/Advisor: AstraZeneca; Bayer; Janssen; Merck; Myovant; Pfizer Inc.; Grant/Research Support: Janssen |
| Harold Burstein | Nothing to disclose |
| Dr. Marc Carrier, M.D., MSc, FRCPC | Consultant: Servier, BMS, Valeo, Sanofi, Anthos, Leo Pharma; Research Grant: Pfizer, Leo Pharma |
| Dr. Aakash Desai | Nothing to disclose |
| Amy DeZern, MD, MHS | Consultant: Geron, Apellis, Bristol-Myers Squibb, Novartis, Regenergon, Sobi, Caribou, Genetech |
| Toby A Eyre | Advisor, Speaker: Roche, Incyte, Abbvie, Janssen, Gilead KITE, Loxo Lilly, Secura Bio, Autolus; Advisor, Speaker, Research funding: Beigene, AstraZeneca. |
| Beth Faiman PhD, MSN, SPRN-BC, AOCN, FAAN | Consultant: Jannssen, Celgene/BMS, Sanofi Genzyme, Karyopharm |
| Narjust Florez, MD | Consultant/advisory board: BMS, AstraZeneca, DSI, Janssen, Pfizer, Neogenomics, Regeneron |
| Nicolas Girard MD, PhD | Consultant/Research Funding to Institute: Roche, AstraZeneca, Amgen; Research Funding to Institute: PharmaMar |
| Erika Hamilton, MD | RESEARCH FUNDING – ALL PAYMENTS TO INSTITUTION: Abbvie, Acerta Pharma, ADC Therapeutics, AKESOBIO, Australia, Amgen, Aravive, ArQule, Arvinas, AstraZeneca, AtlasMedx, Black Diamond, Boehringer, Ingelheim, Clovis, Compugen, Curis, CytomX, Daiichi Sankyo, Dana Farber Cancer Inst, Deciphera, eFFECTOR Therapeutics, Ellipses Pharma, EMD Serono, Fochon, FujiFilm, G1, Therapeutics, H3 Biomedicin, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, InvestisBio, Jacobio, Karyopharm, Leap Therapeutics, Lilly, Lycera, Mabspace, Biosciences, Macrogenics, MedImmune, Merck, Mersana, Merus, Millennium, Molecular, Templates, Myraid Genetic Laboratories, Novartis, Nucana, Olema, OncoMed, Onconova, Therapeutics, ORIC Pharmaceuticals, Orinove, Pfizer, PharmaMar, Pieris Pharmaceuticals , Pionyr Immunotherapeutics, Plexxikon, Radius Health, Regeneron, Repertoire Immune Medicine, Rgenix, Roche/Genentech, Seattle Genetics, Sermonix Pharmaceuticals, Shattuck, Labs, Silverback, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Treadwell Therapeutics, Verastem, Vincerx Pharma, Zenith Epigenetics, Zymeworks CONSULTING/ADVISORY ROLE – ALL PAYMENTS TO INSTITUTION: Arcus, Arvinas, AstraZeneca, Black Diamond, Boehringer Ingelheim, CytomX, Daiichi Sankyo, Dantari, Deciphera Pharmaceuticals, Eisai, H3 Biomedicine, iTeos, Janssen, Lilly, Loxo, Merck, Mersana, Novartis, Pfizer, Puma Biotechnology, Relay Therapeutics, Roche/Genentech, Seattle Genetics, Silverback Therapeutics |
| Maha Hussain, MD | Consultant/Advisor: AstraZeneca; Bayer; Convergent; GlaxoSmithKline; Janssen; Novartis; Pfizer Inc.; Grant/Research Support: AstraZeneca; Arvinas; Bayer; Genentech |
| Suneel Kamath, MD | Advisor: Exelixis; Consultant: Tempus, Guardant |
| Dr. Pashtoon Kasi, MD, MS | Consultant/Advisory Board: Ipsen (institution), Natera, Foundation Medicine, AstraZeneca, MSD Oncology/Merck, Tempus, Bayer, Lilly, Delcath Systems, Axiom Healthcare Strategies, IPBA, QED Therepeutics, Boston Healthcare Associates, Servier, Exact Sciences; Research/Grant Funding: BTG/Boston Scientific (institution), Tesera (institution), AAA/Novartis; Travel/Grant Funding to Present IIT at Conference: AstraZeneca |
| Alok A. Khorana | Honoraria for Consulting: Janssen, Bayer, Sanofi, Pfizer, Anthos, BMS |
| Dr. C. Ola Landgren | Consultant: Amgen, Janssen, Pfizer, BMS, GSK, Karyopharm, Oncopeptides; Speaker: Sanofi |
| Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO | Consultant: AbbVie, Agios/Servier, Astellas, AstraZeneca, BlueNote, BMS/Celgene, CareVive, Flatiron, Genentech, GSK, Novartis, and Pfizer; Advisory Board: AbbVie/Genentech, Agios, and BMS; Honoraria for Speaking: AbbVie, Agios, Astellas, BMS/Celgene, and Incyte; Research funding paid to institution: American Cancer Society, AstraZeneca, BMS, CareVive, Deverra Therapeutics, Duke University, Jazz Pharmaceuticals, the National Institute of Nursing Research/ National Institutes of Health, and Seattle Genetics; Research contracts pending: GSK and Janssen; Reimbursed for travel: AbbVie, Agios/Servier, BMS/Celgene, and Incyte |
| Natasha Leighl, MD, MMSc | Consultant/Advisor: Bayer; GSK; Puma Biotechnology; Grant/Research Support: Amgen; Array; AstraZeneca; Bayer; BMS; Eli Lilly; EMD Serono; Guardant Health; Inivata; Janssen; MSD; Novartis; Pfizer; Roche; Takeda |
| Dr. Suzanne Lentzsch | Equity Ownership: Caelum Biosciences, Mesoblast, Poseida; Advisory/ Consultant: Caelum Bioscience; Research Grant: Karyopharm, Sanofi; Consultant: Sorrento, Janssen, Celularity, Amgen, Takeda, Gsk, CCO, Oncopeptides |
| Joseph Mikhael M.D. | Consultant: Amgen, BMS, Janssen, Karyopharm, Sanofi, Takeda |
| Rohit Moudgil, MD | Nothing to disclose |
| Martina Murphy, MD | Nothing to disclose |
| Antonio Passaro MD, PhD | Consulting or Advisory Role: Roche/Genentech, Bristol Myers Squibb, AstraZeneca, MSD Oncology, Pfizer, Boehringer Ingelheim, Johnson & Johnson/Janssen, Novartis, Lilly Speakers’ Bureau: AstraZeneca, Johnson & Johnson/Janssen, Boehringer Ingelheim |
| Sandip P Patel, MD | Scientific Advisory: Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina , Merck, Pfizer, Rakuten, Tempus; Research Funding: Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech, SQZ Biotechnologies |
| Shruti Rajesh Patel, MD | Nothing to disclose |
| Solange Peters, MD, PhD | Consultant/Advisor: AbbVie, AiCME, Amgen, Arcus, AstraZeneca, Bayer, Beigene, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Illumina, Imedex, IQVIA, Incyte, Ipsen, iTeos, Janssen, Medscape, Medtoday, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Novocure, OncologyEducation, Pharma Mar, Phosplatin Therapeutics, PER, Peerview, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, Vaccibody Grants/Research Support: Principal investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, Merck Sharp and Dohme, Roche/Genentech; Speakers Bureau: AiCME, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Foundation Medicine, GSK, Illumina, Imedex, Ipsen, Medscape, Merck Sharp and Dohme, Mirati, Novartis, PER, Peerview, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, Takeda |
| David Planchard. MD, PhD | Consultant/Advisor: Abbvie; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Janssen; Novartis; Pfizer |
| Dr. Dale Shepard | Consultant: Sanofi SA; Research support: Deciphera Pharmaceuticals, Pionyr Immunotherapeutics, Inhibrix, Conjupro Biotherapeutics, Ram Therapeutics, Shanghai Micropeutics, Astellas |
| Alan Tan, MD | Consultant/Advisor: Bristol Myers Squibb; EMD Serono; Exelixis; Foundation Medicine; Gilead; Merck; Myovant; Natera; Equity: Adaptimune; Bluebird; Editas; Fate Therapeutics; Iovance; Jounce Therapeutics; MEI Pharma; Mirati; Natera |
| Dr. Ann Meredith Garcia Trinidad | Advisory Board: Amgen, Eli Lilly; Speaker: AstraZeneca, Boehringer Ingelheim, MSD, Roche; Writer: Pfizer; Consultant: Sandoz |
| Tzu-Fei Wang, MD, MPH | Research funding: Leo Pharma; Advisory honorarium: Valeo |
| Amer Zeidan, MBBS, MHS | Research funding (institutional): Celgene/BMS, Abbvie, Astex, Pfizer, Kura, Medimmune/AstraZeneca, Boehringer-Ingelheim, Incyte, Takeda, Novartis, Shattuck Labs, Geron, Foran, Aprea; Advisory boards, and/or had a consultancy with and received honoraria: AbbVie, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Servier, Boehringer-Ingelheim, Novartis, Astellas, Daiichi Sankyo, Geron, Taiho, Seattle Genetics, BeyondSpring, Takeda, Ionis, Amgen, Janssen, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Zentalis, Schrodinger, Regeneron, Syros, Schrodinger, Tyme; Clinical trial committee: Novartis, Abbvie, Gilead, Syros, BioCryst, Abbvie, ALX Oncology, Kura, Geron and Celgene/BMS. |
All relevant financial relationships with ineligible companies for this educational content have been mitigated.